Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics Said Q1 Losses Widened as Spending Overpowered Strong Revenue Growth

NEW YORK, Nov. 6 - Myriad Genetics yesterday said that greater spending in its fiscal first quarter overpowered strong revenue growth to widen net loss.


Total receipts in the period ended Sept. 30 increased to $15.5 million from $13.2 million on year ago. Driving that growth were receipts from Myriad's predictive medicine divisions, which grew by $2.2 million, or 43 percent, on sales of the BRACAnalysis breast cancer test and the Colaris products for colon and uterine cancer.


However, revenue from combined research activities in the current first quarter dipped to $7.6 million from $7.7 million last year as Myriad shifted more of its focus to internal drug-development programs.


R&D spending in the quarter increased 33 percent to $10.9 million. Myriad said the increase was due mainly to costs associated with developing its therapeutic pipeline, which contains 15 drug candidates.


First-quarter SG&A spending also jumped by 37 percent to $7.7 million, reflecting an unspecified increase in sales force, Myriad said.


Consequently, net loss for the first quarter 2002 swelled to $5.3 million, or $.22 per share, from $1.2 million, or $.05 per share, year over year, Myriad said.


The company said it had roughly $103.7 million in cash and marketable investment securities as of Sept. 30.


Click here for more information.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.